Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-lymphocyte malignancy caused by human T-lymphotropic virus type I (HTLV-1) infection. 1 In Japan, an intensive chemotherapy such as VCAP-AMP-VECP regimen is widely applied to patients with aggressive ATL; however, the median PFS was at most 7 months. 2 On the other hand, allogeneic hematopoietic stem cell transplantation (allo-HSCT) for those patients achieved several years of disease-free survival. [3] [4] [5] Thus, allo-HSCT has now become an important treatment option for aggressive ATL, however, in daily practice, difficulties associated with advanced age largely limit the number of ATL patients eligible for allo-HSCT. Furthermore, the time-consuming process of acquiring a suitable unrelated donor exceeds the brief window of opportunity (controlled disease status) for allo-HSCT, because ATL tumor cells are characteristically apt to turn resistant to chemotherapeutic agents. 6 Taking above, we assume that in daily practice, a substantial number of ATL patients might miss a good opportunity for allo-HSCT, instead, they might have to undergo allo-HSCT on relapsed disease. Unfortunately, previous studies uniformly divided disease status at transplant into CR vs non-CR. Therefore, in this study, we attempted to clarify outcomes of allo-HSCT for patients with relapsed ATL using information from the database of Japan Society for Hematopoietic Cell Transplantation (JSHCT). Mogamulizumab, 7 a humanized anti-CCR4 monoclonal antibody which greatly impacted on the disease control of aggressive ATL, was widely introduced into daily practice in Japan in the late of 2012. Therefore, to this end, data for all patients who received a first allo-HSCT from 1985 to 2012 were obtained from the Transplant Registry Unified Management Program (TRUMP). 8 This study was planned by the ATL working group of JSHCT, and was approved by the data management committees of TRUMP and the institutional review board of Ehime University and the National Cancer Center, Tokyo, Japan. A total of 131 patients with relapsed ATL met the criteria. We did not include any patients with ATL in remission. Primary end point was the probability of overall survival (OS). Secondary end points included the cumulative incidence of non-relapse mortality (NRM) and relapse. The patients' characteristics were compared using the χ 2 test or Fisher's exact test for categorical variables. The probability of OS was analyzed by the Kaplan-Meier method, and a Cox proportional-hazards regression model. The cumulative incidence of NRM and acute GvHD were evaluated using the model of Fine and Grey the competing-risk model 9 for univariate and multivariate analyses. A two-sided P-value o 0.05 was considered statistically significant. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University; http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN. html), a graphical user interface for R (version 3.0.2; The R Foundation for Statistical Computing, Vienna, Austria). 10 EZR is a modified version of R commander (version 2.0.3) that incorporates statistical functions frequently used in biostatistics.
Patient characteristics are summarized in Table 1 . The median age of patients was 54-years old, median interval from diagnosis to transplant was 286 days (range, 53-3753 days), and median year of transplant was 2007 (range, 1985-2012) . At the date, data cutoff as 31 March 2015, 20 patients (15.3%) survived. Causes of death comprised of 60.4% of relapse, 11.7% of infection, 5.4% of GvHD and 18% of multi-organ failure. The median follow-up period of survivors was 1228 days (range, 56-4142 days). Allo-HSCT for patients with relapsed ATL was unsatisfactory. The probabilities of 1-and 3-year OS were 22% (95% confidence interval (CI), 15.2-29.6%) and 12.5% (95% CI, 7.3-19.1%), respectively ( Figure 1a ). The 3-year OS rate was a third of that previously reported; 36% (95% CI, 32-41%) for all registered ATL patients who received allo-HSCT. 5 Univariate analysis extracted performance status (PS) 0-1 at transplant (P = 0.048) and transplant year ⩾ 2007 (P = 0.023) as favorable prognostic factors for OS (Table 2 ). Multivariate analysis showed that transplant year ⩾ 2007 solely had a favorable impact on OS (hazard ratio, 0.58; 95% CI, 0.384-0.887; P = 0.009). This might reflect the recent progress in transplant technology and supportive care. A 3-year cumulative incidence of NRM was as high as 36.8% (95% CI, 28.2-45.4%) (Figure 1b) . Univariate, but not multivariate analysis, extracted preparatory regimen (myeloablative vs reduced intensity) as a favorable prognostic factor for NRM (0.452 vs 0.282, P = 0.049). The 1-and 3-year cumulative incidences of relapse were as high as 25 and 50.5% (Figure 1c) , resulting in relapse being the leading cause of death (60.4%). No suppressive factors for relapse rate were extracted. Collectively, the present study, for the first time, demonstrated that the outcome of allo-HSCT for patients with relapsed ATL was unsatisfactory, despite its timeproven therapeutic efficacy for ATL patients on the whole. In this context, it seems reasonable that allo-HSCT for aggressive ATL patients should circumvent the timing of relapsed disease.
On the other hand, in the setting of allo-HSCT for ATL, Japanese physicians tended to prefer HLA matched stem cell sources (61.8%), furthermore, 69% of those (42%) were unrelated bone marrow (Table 1) . Given, the inherently longer period needed for acquisition of a suitable unrelated donor might unintentionally result in those patients missing the good opportunity with better PS (0-1) and controlled disease status, because ATL tumor cells are usually sensitive to initial chemotherapy for a while, despite being predisposed to acquire chemo-resistance. 6, 11 Taking account of above, to circumvent allo-HSCT for in patients with relapsed ATL, instead of simply excluding those patients from the eligibility of allo-HSCT, it would be reasonable to actively apply up-front allo-HSCT in the early period from the initial diagnosis, which would be able to provide more better opportunities for patients with aggressive ATL to receive allo-HSCT. In our recent previous study, we have described that an early application of allo-HSCT for patients with aggressive ATL, in which time from diagnosis to allo-HSCT was o 100 days, had a better OS with a statistical significance, accompanied by the lower incidence of NRM in the early period after transplant. 12 Similar observation was described regarding high-risk acute myeloid leukemia. 13 To this end, focusing on the timely acquisition of available donors, we need to consider active employment of alternative stem cell sources, including cord blood and haploidentical family donors. Although haploidentical transplant for aggressive ATL patients still remains at the experimental stage, 14 an early application of cord blood transplantation for those patients lacking a timely and suitable related donor yielded promising outcomes. 11 Given that the optimal timing for allo-HSCT in patients with aggressive ATL lies in the early phase of initial treatment, prospective studies incorporating early application of allo-HSCT for ATL patients who lack suitable sibling donors, in combination with active employment of timely available alternative stem cell sources are warranted.
At the same time, optimization of transplant regimens for allo-HSCT using alternative stem cell sources are being explored.
This study has inherent limitations in the setting of the retrospective analysis of registry data, particularly lacking the detail information of chemotherapies prior to allo-HSCT such as line of prior chemotherapy, however we finally demonstrated the dismal outcome of allo-HSCT for patients with relapsed ATL associated with high incidence of relapse. In addition, although our data supports the idea that early application of allo-HSCT to patients with aggressive ATL is considered to conduct allo-HSCT while ATL is under control, we do not have any data to show whether such a strategy could yield a better overall outcome in patients with a nature of high-risk disease, which should be assessed in prospective studies. Similarly the poor outcome for patients with relapsed peripheral T-cell lymphoma has been reported, 15 thus our strategy might also be able to improve the prognosis of those peripheral T-cell lymphoma patients. This Abbreviations: ATL = adult T-cell leukemia/lymphoma; BM = bone marrow; CB = cord blood; CSP = cyclosporine; HSCT = hematopoietic stem cell transplantation; MAC = myeloablative conditioning; PB = peripheral blood; RIC = reduced intensity conditioning; TAC = tacrolimus. hypothesis should be examined by our currently on-going clinical trials in the near future. Abbreviations: ATL = adult T-cell leukemia/lymphoma; CB = cord blood; CI = confidence interval; CSP = cyclosporine; MAC = myeloablative conditioning; NRM = non-relapse mortality; OS = overall survival; RIC = reduced-intensity conditioning; TAC = tacrolimus.
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